Tumorigenicity and Analysis of the Cell Growth of Human Medulloblastoma

人髓母细胞瘤的致瘤性和细胞生长分析

基本信息

  • 批准号:
    01570809
  • 负责人:
  • 金额:
    $ 1.34万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
  • 财政年份:
    1989
  • 资助国家:
    日本
  • 起止时间:
    1989 至 1990
  • 项目状态:
    已结题

项目摘要

Medulloblastoma are among the most common malignant brain tumors in children. It suggested that the precursors of these tumors consisted of immature bipotential cells which could differentiate into neuronal and glial cells. We established two human medulloblastoma cell lines in order to investigate their characterization and cell differentiation. One was derived from a 2-year-old girl with a cerebellar tumor (designated as ONS-76 cells), and another was from a 9-year-old girl with a metastatic tumor in the right lower frontal lobe from her posterior fossa (designated as ONS-81 cells). The in vitro population-doubling times were 18.6 and 19.2 hours, respectively. These cells were transplantable into the nude mice subcutaneously and intrathecally. Experimental models with meningeal dissemination were produced by intracisternal inoculation of ONS-76 cells into the nude mice. All mice were dead within 65 days after 1x107 tumor cells were inoculated intracisternally. Their median survival t … More ime (MST) was 56 days.Immunohistochemical studies showed that both cells possessed neurofilament protein (NFP) (Mr 145 K and 200K) and neuron-specific enolase (NSE), without glial fibrillar acidic protein (GFAP) or S-100 protein. These cell lines also had epidermal growth factor (EGF) receptor (R), Transferrin-R, and lnsulinーR. These cells could grow in the growth medium without fetal calf serum (FCS). Most these cells possessed class I major histocompatibility complex (MHC) antigens, and these class I antigens were able to be enhanced by human interferon-g (IFN-g). Both cell lines didn't have class II MHC antigen, but these antigens could be induced by human IFN-g. ONS-76 and ONS-81 cells expressed proto-oncogene (N-myc and c-src) products. These cells showed drug-induced differentiation under 50-100 mM of dibutyryl cyclic-adenosine 3', 5'-monophosphate (dbt-cAMP). Fluorescence-activated cell sorter (FACScan) analysis also showed that these both cell lines increased expression of pp60^<c-src> products and NFP (145 K and 200 K). A monoclonal antibody (mAb) (ONS-M-1.0) of lgG2 isotype was raised against medulloblastoma by immunization of mice with ONS--76 cells. This mAb bound these two human medulloblastoma (ONS-76 and -81) cells selectively. Natural killer cells were demonstrated a little ONS-M-1.0 antigens. Biochemical analysis showed that these antigens were sensitive to trypsin but not to neuraminidase, and that they were heat-stable. The high specificity of this antibody^* on medullobalstoma cells might be contributory to the diagnostic and therapeutic strategies for medulloblastoma. Less
髓母细胞瘤是儿童最常见的恶性脑肿瘤之一。这表明这些肿瘤的前体由未成熟的双能细胞组成,可以分化为神经元和神经胶质细胞。我们建立了两种人髓母细胞瘤细胞系,以研究它们的特征和细胞分化。一个来自一名患有小脑肿瘤的 2 岁女孩(指定为 ONS-76 细胞),另一个来自一名 9 岁女孩,该女孩的后颅窝右下额叶有转移性肿瘤(指定为 ONS-81 细胞)。体外群体倍增时间分别为18.6和19.2小时。这些细胞可通过皮下和鞘内移植到裸鼠体内。通过将ONS-76细胞接种到裸鼠脑池内建立脑膜播散实验模型。脑池内接种1x107个肿瘤细胞后,所有小鼠均在65天内死亡。它们的中位生存期 (MST) 为 56 天。免疫组织化学研究表明,这两种细胞都含有神经丝蛋白 (NFP)(Mr 145 K 和 200K)和神经元特异性烯醇化酶 (NSE),不含胶质纤维酸性蛋白 (GFAP) 或 S-100 蛋白。这些细胞系还具有表皮生长因子 (EGF) 受体 (R)、转铁蛋白-R 和胰岛素 R。这些细胞可以在不含胎牛血清(FCS)的生长培养基中生长。大多数这些细胞具有 I 类主要组织相容性复合体 (MHC) 抗原,并且这些 I 类抗原能够被人干扰素-g (IFN-g) 增强。两种细胞系均不具有 II 类 MHC 抗原,但这些抗原可以被人 IFN-g 诱导。 ONS-76 和 ONS-81 细胞表达原癌基因(N-myc 和 c-src)产物。这些细胞在 50-100 mM 二丁酰环腺苷 3', 5'-单磷酸 (dbt-cAMP) 下表现出药物诱导的分化。荧光激活细胞分选仪 (FACScan) 分析还表明,这两种细胞系均增加了 pp60^<c-src> 产物和 NFP(145 K 和 200 K)的表达。通过用 ONS--76 细胞免疫小鼠,产生抗髓母细胞瘤的 IgG2 同种型单克隆抗体 (mAb) (ONS-M-1.0)。该 mAb 选择性结合这两种人髓母细胞瘤(ONS-76 和 -81)细胞。自然杀伤细胞被证明有少量ONS-M-1.0抗原。生化分析表明这些抗原对胰蛋白酶敏感但对神经氨酸酶不敏感,并且它们是热稳定的。该抗体对髓母细胞瘤细胞的高度特异性可能有助于髓母细胞瘤的诊断和治疗策略。较少的

项目成果

期刊论文数量(76)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
山田 正信: "樹立細胞株を用いたPNET及び髄芽腫の生物学的比較検討" 神経免疫研究. 2. 137-142 (1989)
Masanobu Yamada:“使用已建立的细胞系对 PNET 和髓母细胞瘤进行生物学比较研究”《神经免疫学研究》2. 137-142 (1989)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
清水 恵司: "脳腫瘍患者に対する養子免疫療法の長期追跡結果" Biotherapy. 4. 478-482 (1990)
Keiji Shimizu:“脑肿瘤患者过继免疫治疗的长期随访结果”生物治疗 4. 478-482 (1990)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
馬淵 英一郎: "ヒト悪性脳腫瘍に対するin vitro感受性試験" 癌と化学療法. 18. 233-238 (1991)
Eiichiro Mabuchi:“人类恶性脑肿瘤的体外敏感性试验”《癌症与化疗》18. 233-238 (1991)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Yamada M, Shimizu K, et al: "Establishment and biological characterization of human medulloblastoma and PNET cell lines." Neuroimmunol. Res.2. 137-142 (1989)
Yamada M、Shimizu K 等人:“人髓母细胞瘤和 PNET 细胞系的建立和生物学特性。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
清水恵司: "髄芽種患者に対する養子免疫療法" 脳と神経. 41. 991-995 (1989)
Keiji Shimizu:“髓母细胞瘤患者的过继免疫疗法”《大脑和神经》41. 991-995 (1989)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHIMIZU Keiji其他文献

SHIMIZU Keiji的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHIMIZU Keiji', 18)}}的其他基金

Effect of abnormalities in asymmetric cell divisions of neural stem cells on brain tumor initiation
神经干细胞不对称细胞分裂异常对脑肿瘤发生的影响
  • 批准号:
    23659690
  • 财政年份:
    2011
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
New therapeutic strategies for malignant brain tumors by using genetic and molecular biology
利用遗传和分子生​​物学治疗恶性脑肿瘤的新策略
  • 批准号:
    16390411
  • 财政年份:
    2004
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Basic research of malignant glioma-specific gene therapy by using very high titer retrovirus vectors
超高滴度逆转录病毒载体恶性胶质瘤特异性基因治疗的基础研究
  • 批准号:
    12470290
  • 财政年份:
    2000
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development for new transduction of gene by using mouse monoclonal antibody or its humanized antibody
使用小鼠单克隆抗体或其人源化抗体进行新的基因转导的开发
  • 批准号:
    08457363
  • 财政年份:
    1996
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Moleculo-biological analysis for mechanism of proliferation and differentiation in glioma cells and its clinical application
胶质瘤细胞增殖分化机制的分子生物学分析及其临床应用
  • 批准号:
    04454360
  • 财政年份:
    1992
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (B)
Immunological conditions of patients with malignant gliomas ---Therapeutic drugs and Selection of BRMs---
恶性胶质瘤患者的免疫状况---治疗药物及BRMs的选择---
  • 批准号:
    62570656
  • 财政年份:
    1987
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
Identity and their origins of immune cells in the brain
大脑中免疫细胞的身份及其起源
  • 批准号:
    60570671
  • 财政年份:
    1985
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Nanocage-based systemic delivery of TGFβ trap for immunomodulation of brain neoplasms
基于 Nanocage 的 TGFβ 陷阱系统递送用于脑肿瘤的免疫调节
  • 批准号:
    10576313
  • 财政年份:
    2021
  • 资助金额:
    $ 1.34万
  • 项目类别:
Nanocage-based systemic delivery of TGFβ trap for immunomodulation of brain neoplasms
基于 Nanocage 的 TGFβ 陷阱系统递送用于脑肿瘤的免疫调节
  • 批准号:
    10399979
  • 财政年份:
    2021
  • 资助金额:
    $ 1.34万
  • 项目类别:
BRAIN NEOPLASMS, LEUKEMIA & PETROCHEMAL EXPOSURES
脑肿瘤、白血病
  • 批准号:
    6382279
  • 财政年份:
    2000
  • 资助金额:
    $ 1.34万
  • 项目类别:
BRAIN NEOPLASMS, LEUKEMIA & PETROCHEMAL EXPOSURES
脑肿瘤、白血病
  • 批准号:
    6131131
  • 财政年份:
    2000
  • 资助金额:
    $ 1.34万
  • 项目类别:
BRAIN NEOPLASMS, LEUKEMIA & PETROCHEMAL EXPOSURES
脑肿瘤、白血病
  • 批准号:
    6781920
  • 财政年份:
    2000
  • 资助金额:
    $ 1.34万
  • 项目类别:
BRAIN NEOPLASMS, LEUKEMIA & PETROCHEMAL EXPOSURES
脑肿瘤、白血病
  • 批准号:
    6649741
  • 财政年份:
    2000
  • 资助金额:
    $ 1.34万
  • 项目类别:
BRAIN NEOPLASMS, LEUKEMIA & PETROCHEMAL EXPOSURES
脑肿瘤、白血病
  • 批准号:
    6525270
  • 财政年份:
    2000
  • 资助金额:
    $ 1.34万
  • 项目类别:
Experimental Analysis of Intracerebral Immunosurveillance Mechanism and Its Clinical Application to Management of Brain Neoplasms
脑内免疫监视机制的实验分析及其在脑肿瘤治疗中的临床应用
  • 批准号:
    09470295
  • 财政年份:
    1997
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Analysis of relationship between immunosurveillance and tumorigenesis in the brain and new approach to treatment of brain neoplasms
免疫监视与脑肿瘤发生关系分析及脑肿瘤治疗新途径
  • 批准号:
    07457316
  • 财政年份:
    1995
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Intracellular calcium signaling in malignant brain tumor cells and new application to the management of the brain neoplasms
恶性脑肿瘤细胞中的细胞内钙信号传导及其在脑肿瘤治疗中的新应用
  • 批准号:
    05454398
  • 财政年份:
    1993
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了